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Introduction: The occurrence of systemic lupus erythematosus has been only rarely reported in patients with
sickle-cell disease.
Case presentation: We describe the case of a 23-year-old North-African woman with sickle-cell disease and
systemic lupus erythematosus, and discuss the pointers to the diagnosis of this combination of conditions and also
present a review of literature. The diagnosis of systemic lupus erythematosus was delayed because our patient’s
symptoms were initially attributed to sickle-cell disease.
Conclusions: Physicians should be alerted to the possible association of sickle-cell disease and systemic lupus
erythematosus so as not to delay correct diagnosis and initiation of appropriate treatment.
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Sickle-cell disease (SCD) is a prevalent genetic disorder
that includes sickle-cell anemia (the homozygous and
most common form of SCD (SS)), sickle-cell hemoglobin
C (SC) and sickle-cell β thalassemia (S/β thal) [1]. The
protean clinical features of SCD result from chronic vari-
able intravascular hemolysis and microvascular ischemia,
leading to damage in multiple organs [2]. The occurrence
of connective tissue diseases, in particular systemic lupus
erythematosus (SLE), has only been rarely reported in
patients with SCD [2]. The incidence of SLE in patients
with SCD is not known because most of the published
studies are case reports. Due to similar clinical manifesta-
tions, diagnosis of SLE in patients with SCD may be diffi-
cult and is often delayed. We report the case of a patient
who developed symptoms initially attributed to SCD, but
on further investigation underlying SLE was revealed.Case presentation
A 23-year-old North-African woman with no family his-
tory of SCD was admitted to our department of internal* Correspondence: maamarmouna@yahoo.fr
Department of Internal Medicine, Ibn Sina Hospital, Rabat, Morocco
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reproduction in any medium, provided the ormedicine with symptoms of anemia, bone pain, arthral-
gia and fever. Her symptoms had been developing for
six weeks with alteration of her general condition and
abdominal pain. On physical examination our patient
was pale, she had a temperature of 39.5°C, her blood
pressure was 130/75mmHg and heart rate was 100
beats/minute. The patient had slight splenomegaly,
pain on pressure in the long bones and arthritis in her
knees.
Blood test results showed normocytic anemia at 6.6g/
dL with a high reticulocyte count (230,000 cells/mm3),
hyperleukocytosis with granulocytosis (leukocyte count
16,500 cells/mm3, polymorphonuclear cells 9500 cells/
mm3) and moderate thrombopenia (100,000 cells/mm3).
Further investigations showed diminished haptoglobin
(0.08mg/L), elevated lactate dehydrogenase (4670UI/L)
indirect hyperbilirubinemia (21mg/L) with moderate
cytolysis and cholestasis (aspartate aminotransferase
43U/L, alanine aminotransferase 65U/L, phenylalanine
ammonia lyase 217U/L and γ-glutamyl transpeptidase
188U/L). Hemoglobin (Hb) electrophoresis test results
showed Hb S at 50.3 percent, Hb C at 44 percent andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Maamar et al. Journal of Medical Case Reports 2012, 6:366 Page 2 of 9
http://www.jmedicalcasereports.com/content/6/1/366Hb A1 at 0 percent, confirming a diagnosis of SCD
(hemoglobin S/C).
Our patient’s erythrocyte sediment rate was 110mm/
first hour, her C-reactive protein level was 38mg/L (range
<6mg/L), fibrinogen was 6.4g/L (24g/L) and serum pro-
tein electrophoresis showed a polyclonal IgG 24g/L
(range 9 to 13g/L) with normal immunofixation. Results
of a chest X-ray were normal. Abdominal ultrasonog-
raphy, transthoracic and transesophageal echocardiog-
raphy results were also normal. A thoraco-abdominal
scan revealed numerous splenic infarctions. The results
of a bone scan showed diffuse bone infarcts.
Her symptoms were attributed to SCD and hence our
patient received blood transfusions, antibiotics and
analgesics, but with no improvement. Her fever and
arthritis failed to respond to this treatment. Instead, the
evolution of her condition was marked by the develop-
ment of arthritis in her hands and relapse of anemia.
Blood culture test results were negative, and the result
of a tuberculin skin test was an 8mm induration. There
was no BK virus found in repeated sputum and urine
examinations, and procalcitonin test results were negative.
Serology test results for human immunodeficiency virus,
hepatitis B, hepatitis C, brucellosis and typhoid fever were
all negative. Cytobacteriological urine analysis revealed no
bacteria but microscopic hematuria (670 cells/mm3)
and leukocyturia (50 cells/mm3). Proteinuria results were
negative.
The results of a Coombs test performed on admission
were strongly positive for IgG. Immunological investiga-
tions revealed a positive anti-nuclear antibody (1/2600)
result, and a positive anti-Sm result. Anti-DNA antibody
tests were negative. A test for anti-extractable nuclear
antigen antibodies (anti-ENA) was negative. C3 levels
and C4 levels were normal (respectively, 0.95g/L and
0.3g/L). Tests for anti-phospholipid antibodies were
negative. A diagnosis of SLE associated to SCD was
established, with five of the diagnostic criteria of the
American College of Rheumatology being met. Steroids
were administered as a pulse of methylprednisolone
1g/day for three days followed by oral prednisone at
1mg/kg/day with hydroxychloroquine. Her symptoms
quickly improved. At her 18-month follow up, she was
in clinical remission on prednisone 5mg per day and
hydroxychloroquine; she had not experienced a sickle-
cell crisis and her lupus is still quiescent.
Discussion
In the present report we described the case of a Mo-
roccan woman with SCD and coexistent SLE. The
overlap of SLE and SCD is of interest, but the limited
number of patients that have been reported previously
implies that the association is uncommon [3]. Only
40 similar cases have been reported in the literatureover the last 50 years [2-16] (Table 1). The African/
Afro-Caribbean/African-American population is predis-
posed to contracting both SCD and SLE, explaining
the fact that most patients with this association are
African women (70 percent in Table 1 and 73 percent
in the series by Michel et al.). All reported cases were
relatively young at the time of lupus diagnosis (mean
age 23 years, range eight to 57 years). All of them
had SCD several years before SLE. Articular involve-
ment is the most frequent lupus-related symptom,
present in 84 percent of cases, followed by serositis
(36 percent), and glomerulonephritis class III or IV (11
percent). Cutaneous manifestations are not frequently
mentioned. Positive anti-nuclear antibody (ANA) results
were found in 34 cases. Prognosis was favorable in 80
percent of cases (Table 1). Patients with SCD present
with a defective activation of the alternate pathway of the
complement system; this is the reason why these patients
are at increased risk of capsulate bacteria infection, such
as from pneumococci [15]. Some authors have suggested
the hypothesis that this defect may lead to immune com-
plex disorders secondary to failure to eliminate antigens,
predisposing these patients to autoimmune diseases, but
this has not been confirmed in other studies [3,11,13].
The clinical features of SLE and SCD have certain ele-
ments in common. Diverse manifestations such as polyar-
thritis, anemia, fever, visceral pain, renal, cardiovascular
and pulmonary involvement are common in both condi-
tions. Owing to the overlap of clinical features in the two
diseases it may easy to confuse them, as occurred with our
patient.
Further, the frequency and titers of antibodies in SCD
have been reported as relatively higher than in popula-
tion controls, making the diagnosis more challenging in
clinical practice [17].
Toly-Ndour et al. reported that 50 percent of 88
patients with SCD had positive anti-nuclear antibody
results and 20 percent had titers greater than one in
200, but only one patient developed rheumatoid arth-
ritis five years later and no patients developed SLE [18].
In this series, patients treated with hydroxyurea had
ANA-positive results less frequently than non-treated
patients (P=0.053) [18].
Large prospective epidemiological studies are necessary
to determine whether the prevalence of immune complex
diseases is increased in patients with SCD.
Conclusions
This report illustrates the importance of considering
associated diseases when clinical findings are unex-
plained by SCD alone, or are unresponsive to the con-
ventional treatment. Early diagnosis and the initiation of
appropriate treatment may decrease morbidity and mor-
tality in these patients.
Table 1 Summary of previous case reports of SCD and SLE [2-16]
Lead
author/year/
reference
Sex/origin Age of
SCD
onset
Age of
SLE
onset
SLE
features
Immunologic
features
Hemoglobin
type
Treatment Outcome
Cherner 2010 [3] F/Afro-Caribbean 13 21 Arthritis, fever ANA+ SS Prednisone Clinical
improvement
Malar rash Anti-CCP+ Methotrexate
Gut vasculitis Anti-RNP+ Rituximab
ACL+ Cyclophosphamide
Cherner 2010 [3] F/Afro-Caribbean 7 41 Skin rash ANA+ SS Prednisone Clinical
improvement
Renal disease
(biopsy not
performed)
Anti-DNA+
Anti-Ro+
Appenzeller 2008 [4] F/African-American NA 16 Fever, arthritis ANA+ SS Prednisone Clinical
improvement
Photosensitivity Anti-SM+ Azathioprime
Cardiomyopathy
Pericarditis
Appenzeller 2008 [4] F/African-American 15 21 Arthritis ANA+ SS Prednisone Clinical
improvement
Pleuritis Anti-DNA+ SS Hydroxychloroquine
Lymphadenopathy Anti-Sm+
Appenzeller 2008 [4] F/African-American NA 57 Arthritis Anti-Sm+ SS Prednisone
Photosensitivity Hydroxychloroquine Clinical
improvement
Discoid lesions
Raynaud’s
phenomenon
Michel 2008 [2] F/NA NA 30 Arthritis ANA+ SS Prednisone Deceased
Pericarditis Anti-DNA+
Pleuritis Anti-SSA+
GN class II
Michel 2008 [2] M/NA NA 40 Arthritis ANA+ SS Prednisone Remission
Discoid lesions Hydroxychloroquine
Thrombocytopenia
M
aam
ar
et
al.Journalof
M
edicalCase
Reports
2012,6:366
Page
3
of
9
http://w
w
w
.jm
edicalcasereports.com
/content/6/1/366
Table 1 Summary of previous case reports of SCD and SLE [2-16] (Continued)
Michel 2008 [2] F/NA NA 32 Thrombocytopenia ANA+ SC Hydroxychloroquine Remission
Anti-DNA+
Michel 2008 [2] F/NA NA 35 Arthritis ANA+ SS Prednisone Deceased
Cutaneous vasculitis Anti-DNA+ Hydroxychloroquine
Raynaud’s phenomenon Anti-Sm+ Methotrexate
GN class II Anti-SSA+
Anti-RNP
Michel 2008 [2] F/NA NA 27 Arthritis ANA+ SS Prednisone Remission
Anti-DNA+ Hydroxychloroquine
Michel 2008 [2] F/NA NA 25 Arthritis ANA+ SS Prednisone Remission
GN class III Anti-DNA+ Hydroxychloroquine
Jaccoud
arthropathy
ACL+
Major depression
Michel 2008 [2] M/NA NA 26 Arthritis ANA+ SC Hydroxychloroquine Clinical
improvement
Anti-DNA+
Anti-RNP+
ACL+
Michel 2008 [2] F/NA NA 28 Arthritis ANA+ SS Prednisone Persistent
renal disease
GN class IV Anti-DNA+ Hydroxychloroquine
Bullous lupus Anti-Sm+ Dapsone
Anti-RNP+
Michel 2008 [2] F/NA NA 32 Arthritis ANA+ SS Prednisone Remission
Kikuchi’s disease RF+
Autoimmune
hepatitis
Michel 2008 [2] F/NA NA 40 Arthritis ANA+ SS Hydroxychloroquine Clinical
improvement
Discoid lupus ANA+
Venous
thrombosis
Anti-Ro+
ACL
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Table 1 Summary of previous case reports of SCD and SLE [2-16] (Continued)
Michel 2008 [2] F/NA NA 38 Arthritis ANA+ SS Prednisone Clinical
improvement
Hydroxychloroquine
Michel 2008 [2] F/NA NA 17 Arthritis ANA+ SS Prednisone Clinical
improvement
Thrombocytopenia Anti-Ro+ Hydroxychloroquine
Anti-La+
ACL+
Michel 2008 [2] F/NA NA 35 Pedal and
peri-orbital
edema
ANA+ SC Prednisone Dialysis
Ascites and
renal failure
Anti-DNA+ Cyclophosphamide
GN class IV
Oqunbiyi 2007 [6] M/African NA 8 Malar rash Prednisone Clinical
improvement
Arthritis Hydroxychloroquine
Seizures
Fever
Khalide 2005 [7] F/NA 16 24 Heart failure Anti-DNA+ SC Prednisone Clinical
improvement
Renal failure Anti-Sm+
Pericarditis Lupus
anticoagulant+
Pulmonary
emboli
Polyneuropathy
Generalized
seizures
Khalide 2005 [7] M/NA NA 16 Discoid rash ANA+ SS Prednisone Clinical
improvement
Polyarthritis Anti-DNA+ Hydroxychloroquine,
Partial seizures azathioprine
Khalide 2005 [7] M/NA NA 23 Skin rash ANA+ SS Hydroxychloroquine Lost to
follow up
Pleuritis ACL+
Arthritis
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Table 1 Summary of previous case reports of SCD and SLE [2-16] (Continued)
Raynaud’s
phenomenon
Khalide 2005 [7] F/NA NA 28 Arthritis ANA+ SS Prednisone Clinical
improvement
Oral ulcers Anti-DNA+
GN class III ACL
Saxena 2003 [8] M/African-American NA 9 Arthritis ANA+ SS Prednisone Clinical
improvement
Fever Anti-DNA+ Cyclophosphamide
Acute chest
syndrome
Anti-SSA+
Pericarditis
Seizures
Saxena 2003 [8] F/African-American NA 7 Fever ANA+ SS Prednisone Clinical
improvement
Arthritis Anti-DNA+ Cyclophosphamide
Alopecia Azathioprine
GN class II
Saxena 2003 [8] F/African-American NA 11 Fever ANA+ SS Prednisone Clinical
improvement
Arthritis Cyclophosphamide
Skin rash
Seizures
Cardiomegaly
Saxena 2003 [8] F/African-American NA 14 Seizures ANA+ SS Prednisone Septic
shock due to
pneumococcal
bacteremia
Malar rash Anti-DNA+ Cyclophosphamide
Splenomegaly Azathioprine
Arthritis Plasmapheresis
Pericarditis Splenectomy
Saxena 2003 [8] M/African-American NA 17 Malar rash ANA+ SS Prednisone Hemodialysis
dependent
Alopecia Cyclophosphamide
Pericarditis
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Table 1 Summary of previous case reports of SCD and SLE [2-16] (Continued)
Cardiomegaly
GN class V
Shetty 1998 [9] F/Afro-Carribbean Nine
months
10 Arthritis LE cells in
pericardial
effusion
SS Prednisone Clinical
improvement
Pulmonary
infiltrate
Pericarditis
Myocarditis
Pham 1997 [10] F/Afro-Caribbean NA 18 Arthritis ANA+ SS Prednisone Clinical
improvement
Nephrotic
syndrome
Anti-DNA
Katsanis 1987 [11] F/Afro-Caribbean NA 16 Arthritis ANA+ SS Prednisone Clinical
improvement
Malar rash Anti-DNA+ Hydroxychloroquine
Photosensitivity Anti-Sm+
Pleuritis
Pericarditis
Renal class II
Katsanis 1987 [11] F/Afro-Caribbean NA 15 Arthritis ANA+ SS Prednisone Clinical
improvement
Pleuritis Anti-DNA
borderline
SC Prednisone Clinical
improvement
Warrier 1984 [12] F/Afro-Caribbean NA 11 Malar rash ANA+
Alopecia Anti-DNA+
Arthralgia Anti-ENA+
Seizures
Hepatosplenomegaly
Luban 1980 [13] F/African-American NA 8 Discoid lesions Positive LE SC Prednisone Clinical
improvement
Pericarditis ANA+
Myocarditis
Luban 1980 [13] F/African-American NA 14 Fever ANA+ SS Prednisone Clinical
improvement
Renal disease Positive LE
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Table 1 Summary of previous case reports of SCD and SLE [2-16] (Continued)
Karthikeyan 1978 [14] F/African 4 15 Arthritis ANA+ SS Prednisone Clinical
improvement
Raynaud’s
phenomenon
Positive LE
cell test
Photosensitivity
Wilson 1976 [15] F/African-American 30 40 Arthritis Positive LE cells SS Prednisone Deceased
Pleuritis
Libman-Sacks
endocarditis
Wilson 1976 [15] F/African-American Four
months
16 Arthritis ANA+ SS Prednisone Clinical
improvement
Hepatitis Anti DNA +
Pneumonitis
Wilson 1976 [16] F/African-American NA 27 Arthritis Histopathologic
evidence for SLE on
post-mortem
examination
SS No
treatment for SLE
Deceased
Malar rash
Pulmonary congestion
Hepatomegaly
Nephrotic syndrome
Cerebral and subarachnoid hemorrhage
ACL=anti-cardiolipin antibodies; ANA=anti-nuclear antibodies; anti-ENA=anti-extractable nuclear antigen antibodies; GN=glomerulonephritis; NA=not available; RF=rheumatoid factor; anti-RNP=anti-ribonucleoprotein
antibodies; SCD=sickle-cell disease; SLE=systemic lupus erythematosus; anti-SSA=anti-Sjögren syndrome antigen A antibodies.
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